

**Virginia Medicaid**  
**Pharmacy & Therapeutics Committee Meeting**  
Agenda  
600 East Broad Street – 7<sup>th</sup> Floor Conference Rooms  
Richmond, VA 23219  
**April 24, 2014 – 10 AM**

**Welcome and Comments**

**Cindi Jones, Director**

**Call to Order**

**Tim Jennings, Pharm.D, Chair**

**Drug Utilization Review (DUR) Board Report**

**Avtar Dhillon, M.D., DMAS DUR Board**

**Magellan Medicaid Administration Update**

**Debbie Moody, RPh, Clinical Manager**

**Approval of Minutes from October 24, 2013 Meeting**

**P&T Committee Members**

**PDL Management**

**P&T Committee Members**

- **Old Business**

- Update on ADHD drugs prescribed for non-FDA approved ages
- Narcotic Utilization – report “normalized” for members per prescriber
- Prescription Monitoring Program (PMP)
  - § Policies in Other States
  - § Update on new service authorization requirement to include PMP documentation

- **PDL Phase I – New Drug Review (*Therapeutic Class*)**

- Epaned™ 1 mg/mL oral solution (*Angiotensin-Converting Enzyme Inhibitor*)
- Aerospan™ (flunisolide) (*Glucocorticoids, Inhaled*)
- Olysio™ (simeprevir) & Sovaldi™ (sofosbuvir) (*Hepatitis C Agents*)
- Niacin ER (*Niacin Derivatives*)
- Gatifloxacin 0.5% Ophthalmic Solution (*Ophthalmic Antibiotics*)
- Adempas® & Opsumit® (*PAH Agents*)
- Velphoro® chewable tablet (*Phosphate binder*)
- Aciphex® Sprinkle, esomeprazole strontium & rabeprazole delayed-release tab (*Proton Pump Inhibitors*)
- Tolterodine ER (*Urinary Antispasmodics*)

- **PDL Phase II – Annual Review (*Therapeutic Class*)**

- ***Analgesics***
  - § Barbiturate & Non-salicylate Analgesics (*and combinations*)
  - § Narcotics (*includes long acting, short acting, combinations, and lozenges*)
  - § Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (*includes Cox-2 inhibitors*)
  - § Opioid Analgesics & Dependency
  - § Topical Agents & Anesthetics
- ***Antibiotics/Anti-infectives***
  - § 2<sup>nd</sup> and 3<sup>rd</sup> Generation Cephalosporins
  - § 2<sup>nd</sup> and 3<sup>rd</sup> Generation Quinolones (systemic)
  - § Ketolides & Macrolides (adult and pediatric)
  - § Oral Antifungals
  - § Otic Quinolones
  - § Topical Antibiotics

- **PDL Phase II – Annual Review (continued)**

- **Antivirals**

- § Antivirals for the Treatment of Herpes or Influenza
- § Topical Antivirals

- **Bone Resorption Suppression and Related Agents**

- § Bisphosphonates
- § Calcitonins
- § Others

- **Cardiac Medications**

- § Anticoagulants (*includes low molecular weight heparins, Factor XA inhibitors and oral anticoagulants*)
- § Platelet Inhibitors

- **Central Nervous System**

- § Antihyperkinesia/CNS Stimulants
- § Antimigraine
- § Non-Ergot Dopamine Receptor Agonists
- § Skeletal Muscle Relaxants
- § Smoking Cessation

- **Dermatologic**

- § Acne Agents (*includes benzoyl peroxide, clindamycin, topical retinoids & combinations*)
- § Topical Agents For Psoriasis

- **Endocrine and Metabolic Agents**

- § Androgenic Agents
- § Antihyperuricemics
- § Contraceptives (*oral, vaginal & transdermal*)
- § Erythropoiesis Stimulating Proteins
- § Injectable Hypoglycemics (*includes insulins, incretin mimetics, GLP-1 receptor agonists*)
- § Oral Hypoglycemics (*includes 2<sup>nd</sup> generation sulfonylureas, alpha-glucosidase inhibitors, biguanides, biguanide combinations, meglitinides, thiazolidinediones, DPP-IV inhibitors and combinations*)
- § Progestational Agents
- § Vaginal Estrogens

- **Gastrointestinal**

- § Motility Agents – GI Stimulants (*This class was moved to the fall meeting and covered as part of Antiemetic/Antivertigo Agents*)

- **Immunologic Agents**

- § Multiple Sclerosis Agents
- § Self Administered Drugs for Rheumatoid Arthritis

**Confidential Meeting (Pricing Information Discussion)**

**P&T Committee Members & DMAS Staff**

**Criteria Discussion of Phase I New Drugs**

**P&T Committee Members**

**Criteria Discussion of Phase II New Drugs**

**P&T Committee Members**

**Next Meeting – October 16, 2014 (tentative)**

**Chair**

**Oral Presentations:** The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on *only* the drug classes in Phase II which are scheduled for review at the April meeting and new drugs in PDL Phase I listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Phase II Annual Review – April 2013 to present
- New Drugs in PDL Phase I Drug Classes – April 2012 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to [pdlinput@dmas.virginia.gov](mailto:pdlinput@dmas.virginia.gov) and [dfmoody@magellanhealth.com](mailto:dfmoody@magellanhealth.com) by 5 p.m. EST on **Thursday, April 2, 2014.**